Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker

Trial Profile

Randomized, Placebo Controlled Blinded Study to Assess the Efficacy of Valsartan to Prevent Left Ventricle Remodeling in Patients With Dual Chamber Pacemaker

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 06 Jan 2017

At a glance

  • Drugs Valsartan (Primary)
  • Indications Atrioventricular block; Heart block; Heart failure
  • Focus Pharmacodynamics
  • Most Recent Events

    • 01 Jan 2017 Planned End Date changed from 1 Dec 2017 to 1 Feb 2019.
    • 01 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2018.
    • 01 Jan 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top